Pharmaceutical Biotech

Small Molecules vs. Biologics

For most of pharmaceutical history, drugs were small molecules — organic compounds under 900 daltons. They can be taken orally, cross cell membranes, be synthesized chemically, stored at room temperature, and when their patents expire, generics follow.

Biotech opened a new category: biologics. These include therapeutic proteins (insulin, growth hormone), monoclonal antibodies (Herceptin, Humira, Keytruda), vaccines (mRNA and recombinant subunit), cell therapies (CAR-T), and gene therapies (CASGEVY, Zolgensma). Biologics are typically 50,000–150,000 daltons for antibodies. They generally can't be taken orally, require injection, must be produced by living cells, and require cold chain storage.

The bifurcation matters because it shapes everything about how companies operate. A small-molecule pharma company emphasizes medicinal chemistry and large compound libraries. A biologics company emphasizes molecular biology, protein engineering, cell culture manufacturing, and cold chain logistics. Most modern major pharmaceutical companies do both — but the cutting edge is increasingly in biologics.

Monoclonal Antibodies: The Biologics Workhorse

Monoclonal antibodies (mAbs) are the largest biologic drug category. Six of the ten best-selling drugs globally are mAbs. The annual market exceeds $200 billion. The concept: antibodies are proteins your immune system makes to recognize and bind specific molecules. mAb drugs harness this specificity to bind disease-relevant targets.

Applications: cancer (Herceptin blocks HER2; checkpoint inhibitors Keytruda and Opdivo unleash T cells against tumors; antibody-drug conjugates deliver toxic payloads directly to cancer cells), autoimmune disease (Humira blocks TNF-alpha for rheumatoid arthritis and Crohn's disease; Dupixent blocks IL-4/IL-13 for eczema and asthma), and infectious disease (anti-RSV antibodies, anti-Ebola antibodies).

Development steps: target identification → antibody discovery (immunizing animals, phage display, or AI protein design) → humanization of animal-derived antibodies → optimization → CHO cell line development → Phase I–III trials → manufacturing scale-up. The success of mAbs has driven a generation of innovation: antibody-drug conjugates, multispecific antibodies that bind multiple targets simultaneously, and next-generation checkpoint inhibitors.

Vaccines: From Recombinant to mRNA

Traditional vaccines include live attenuated, inactivated, toxoid, and subunit variants. The first major recombinant vaccine — hepatitis B — was approved in 1986 and was the first FDA-approved recombinant DNA product after insulin.

The mRNA vaccine platform represents a paradigm shift. Instead of delivering protein antigens, mRNA vaccines deliver the genetic instructions for cells to produce the antigen themselves. The manufacturing process is essentially the same regardless of which antigen you're encoding — only the mRNA sequence changes. This made it possible to design the COVID-19 vaccine within days of the viral genome being published and manufacture at scale in under a year.

Moderna, BioNTech, and competitors are now pursuing mRNA for influenza, RSV, HIV, and personalized cancer vaccines. The platform has real limitations — less stability, cold chain requirements — but it has demonstrated proof-of-concept for therapeutic applications beyond vaccines, including cancer immunotherapy.

Manufacturing Biologics

Cell line development. Most therapeutic proteins are produced by engineered CHO cells (Chinese hamster ovary) for antibodies. Developing a high-producing cell line takes years of selection and optimization and is treated as critical intellectual property.

Bioreactor culture. Cells are grown in bioreactors from a few hundred to tens of thousands of liters. Temperature, pH, dissolved oxygen, and nutrients must be tightly controlled. Even small variations affect the protein's final structure and function. Downstream processing purifies the protein to >99.9% purity through chromatography and filtration, removing host cell proteins, DNA, viruses, and contaminants.

The result: biologic drugs are expensive not just because of R&D but because manufacturing is extraordinarily capital-intensive. A single bioreactor facility can cost over $1 billion to build. Quality control alone requires hundreds of analytical tests per batch. This is also why biosimilar competition has been slower — manufacturing a biosimilar requires building equivalent infrastructure, not just synthesizing the same molecule.

Wait, Actually…

Biologics, especially gene and cell therapies, break standard pharmaceutical pricing models. CASGEVY costs $2.2 million per patient — but it's a one-time treatment. Across a patient's lifetime, it may actually be cheaper than decades of chronic sickle cell care.

But upfront pricing breaks insurance systems built for annual budgets. A single $2 million payment shifts a small insurance pool's finances dramatically. Several creative models have emerged: outcomes-based contracts (pay only if it works), payment over time, annuity payments, and performance-linked rebates.

These models exist but aren't yet standard. The fundamental tension — biotech can produce one-time cures but the financial infrastructure is built for ongoing treatments — remains largely unresolved. The next generation of gene and cell therapies will force the issue.

---